Barinthus Biotherapeutics plc Stock Price, News & Analysis

Barinthus Bio (NASDAQ: BRNS) reported Q1 2025 financial results and corporate updates. The company's lead asset VTP-1000, targeting celiac disease, is progressing with Phase 1 single ascending dose data expected in Q3 2025. The company presented encouraging results from two Phase 2 trials (HBV003 and IM-PROVE II) for chronic hepatitis B treatment at EASL 2025. Key financial highlights include cash position of $100.6 million as of March 31, 2025, providing runway into 2027. Q1 2025 showed reduced R&D expenses at $8.3 million (vs $11.1 million in Q1 2024) and increased G&A expenses at $12.6 million (vs $6.0 million in Q1 2024). The company reported a net loss of $19.6 million ($0.49 per share) compared to $15.5 million ($0.40 per share) in Q1 2024. Barinthus is strategically refocusing on immunology and inflammation indications while seeking partners for its viral vector platforms.

Barinthus Bio (NASDAQ: BRNS) has reported its full year 2024 financial results and corporate updates, highlighting its strategic transformation into an immunology and inflammatory disease-focused company. The company's lead asset, VTP-1000, a potentially curative immunotherapy for celiac disease, is progressing with first data expected in Q3 2025.

Key financial highlights include:

• Cash position of $112.4 million as of December 31, 2024
• Revenue of $15.0 million in 2024, up from $0.8 million in 2023
• Net loss of $61.1 million ($1.55 per share)
• Research and development expenses of $42.2 million

The company's SNAP-TI platform shows promise in promoting antigen-specific immune tolerance. In chronic hepatitis B trials, VTP-300 demonstrated encouraging results with eight participants achieving undetectable HBsAg levels. The company's cash runway is expected to extend into 2027.

Barinthus Biotherapeutics has announced its participation in the upcoming Investor Summit Virtual event scheduled for March 11, 2025. The company will be represented by CEO Bill Enright and CFO Gemma Brown at this significant investor conference.

Barinthus Bio announced a strategic shift to focus on Immunology and Inflammation (I&I) with a priority on developing VTP-1000 for celiac disease, expecting Phase 1 data by mid-2025. The company will halt further development of VTP-300 for chronic hepatitis B (CHB) until a partner is found. To extend its cash runway to early 2027, Barinthus will cut costs by reducing its workforce by 65% and closing its U.K. site, focusing future operations in Germantown, Maryland.

Financially, the company reported $112 million in cash and equivalents as of December 31, 2024. This restructuring aims to streamline operations and align resources with its new strategic focus. Key 2025 milestones include:

• Mid-2025: Phase 1 data for VTP-1000 in celiac disease.
• Q3 2025: Start of multiple ascending dose Phase 1 trial for VTP-1000.
• Q2 2025: Results from Phase 2b HBV003 and Phase 2a IM-PROVE II trials for VTP-300 in CHB.
• Q2 2025: Results from Phase 1 PCA001 trial for VTP-850 in prostate cancer.

CEO Bill Enright emphasized the company's commitment to leveraging its SNAP-TI platform for autoimmune diseases and expressed gratitude to departing executives and staff.

Barinthus Biotherapeutics (NASDAQ: BRNS) has promoted Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer (CSO), effective December 1, 2024. Dr. Lynn, co-inventor of the SNAP-TI technology, succeeds Nadège Pelletier, Ph.D., who served as CSO since early 2023. The company has achieved notable progress with VTP-300 in chronic hepatitis B treatment and recently initiated a Phase 1 trial for VTP-1000 in celiac disease. Dr. Lynn previously led Avidea Technologies from 2017 until its acquisition by Barinthus Bio in 2021.

Barinthus Biotherapeutics announced significant results from its ongoing Phase 2b HBV003 clinical trial for chronic hepatitis B treatment. The study, involving 121 participants, evaluated VTP-300 combined with low-dose nivolumab. Key findings include: eight participants achieved complete HBsAg loss, two met functional cure criteria, and two participants who discontinued NUC therapy developed HBsAb positivity. Among 40 participants assessed for NUC discontinuation, 24 were eligible, and nine chose to discontinue. Six remained off NUC therapy, with five maintaining this status for over six months. The treatment was generally well-tolerated with no treatment-related SAEs reported.

Arbutus Biopharma and Barinthus Bio announced new preliminary data from Phase 2a IM-PROVE II trial showing enhanced results when combining imdusiran, VTP-300, and low-dose nivolumab in treating chronic hepatitis B virus. 23% of participants receiving this combination achieved HBsAg loss by Week 48, with significantly greater mean declines in HBsAg levels (p<0.017) compared to other cohorts. The trial included 22 non-cirrhotic participants in Group C, with 13 eligible for nivolumab treatment. The combination therapy was generally well tolerated with no immune-related adverse events reported.

Barinthus Bio (NASDAQ: BRNS) reported Q3 2024 financial results and corporate updates. The company completed enrollment in the HBV003 trial of VTP-300 for chronic hepatitis B with 121 participants, and initiated the Phase 1 AVALON trial of VTP-1000 for celiac disease. Financial highlights include $106.1M in cash as of September 30, 2024, $15M in revenue from Vaxzevria® royalties, and a net loss of $8.1M ($0.21 per share). R&D expenses were $11.1M, down from $11.7M in Q2. The company expects current resources to fund operations into Q2 2026.

Barinthus Biotherapeutics (NASDAQ: BRNS) announced that updated clinical data from its chronic hepatitis B program will be presented at The Liver Meeting® 2024 in San Diego. The late-breaking presentation will focus on VTP-300 combined with low-dose nivolumab and its association with HBsAg loss in specific chronic hepatitis B patients. The company will also participate in several medical congresses including the International Workshop on HBV Cure 2024 and the BSI Immune Therapies Summit. Additionally, management will attend investor conferences including Guggenheim's Healthcare Innovation Conference and Jefferies London Healthcare Conference for presentations and one-to-one meetings.